Inhibition of growth of human breast cancer cells in culture by neutron capture using liposomes containing 10B

Yanagië, Hironobu; Kobayashi, Hisao; Takeda, Yasutaka; Yoshizaki, I.; Nonaka, Yasunobu; Naka, Sadahiro; Nojiri, A; Shinnkawa, H; Niwa, Hitoshi; Ariki, Kaori; Yasuhara, Hiroshi; Eriguchi, Masazumi

doi:10.1016/s0753-3322(01)00161-5

Cited by 16 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous research groups focused their activity on the development of liposomal formulations to improve the delivery of the already-mentioned BSH compound. For example, Mehta et al [56] studied the biodistribution of conventional and PEGylated liposomes encapsulating BSH, while Yanagië et al [57,58] encapsulated a cesium salt of BSH (Cs 2 10 B 12 H 11 SH) into multilamellar immunoliposomes ([ 10 B]immunoliposomes) for pancreatic cancer targeting, justifying the choice of preparing multilamellar vesicles by considering that they present a larger lipophilic compartment than unilamellar ones, and are therefore more suitable for the inclusion of lipophilic active compounds [122].…”

Section: Liposomesmentioning

confidence: 99%

Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment

Ailuno

Balboni

Caviglioli

et al. 2022

Cells

View full text Add to dashboard Cite

Boron neutron capture therapy is a low-invasive cancer therapy based on the neutron fission process that occurs upon thermal neutron irradiation of 10B-containing compounds; this process causes the release of alpha particles that selectively damage cancer cells. Although several clinical studies involving mercaptoundecahydro-closo-dodecaborate and the boronophenylalanine–fructose complex are currently ongoing, the success of this promising anticancer therapy is hampered by the lack of appropriate drug delivery systems to selectively carry therapeutic concentrations of boron atoms to cancer tissues, allowing prolonged boron retention therein and avoiding the damage of healthy tissues. To achieve these goals, numerous research groups have explored the possibility to formulate nanoparticulate systems for boron delivery. In this review. we report the newest developments on boron vehiculating drug delivery systems based on nanoparticles, distinguished on the basis of the type of carrier used, with a specific focus on the formulation aspects.

show abstract

Section: Liposomesmentioning

confidence: 99%

Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment

Ailuno

Balboni

Caviglioli

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…在纳米医学的研究基础上, 以纳米材料为载体的含硼纳米药物也迅速引起了科研工作者们极大的研究热情, 各种类型的含硼纳米药物被合成以评估其成为新型高效硼携带剂的潜力 [5,156,157] . 162~164] , 前文中具有出色肿瘤特异性的EGF [179,180] 、叶酸 [181,182] 和西妥昔单抗 [183] 外肿瘤, 如乳腺癌 [189,190] ; 通过CED瘤内给药或短暂打开血脑屏障, 也可适用于颅内肿瘤. .…”

Section: 由于神经胶质瘤细胞中Egfr基因的表达存在异质性其肿瘤由Egfr型、egfr VIII 型和Egfr阴性的unclassified

Development history of boron delivery agents

Li¹,

Tu²,

Liu³

2020

Sci. Sin.-Chim

View full text Add to dashboard Cite

show abstract

“…In recent years, a new approach to the delivery of boron to tumor cells has been developed, which is based on the introduction of water-soluble boron-containing compounds (such as [B 10 H 10 ] 2-salts or BSH) into the core of liposomes [2,6,24] or lipophilic compounds with 10 B (such as 7-n-C 16 H 33 -nido-7,8-C 2 B 9 H 12 [25]) into a two-layer lipid membrane forming a liposome (Fig. 4).…”

Section: Classification Of Boron Neutron Capture Therapy Agentsmentioning

confidence: 99%

Compounds for neutron capture therapy and their distribution in tumors and surrounding tissues of animals (A review)

Koryakin

2006

Pharm Chem J

View full text Add to dashboard Cite

Boron-containing compounds for neutron capture therapy (NCT) can be divided into three groups: compounds without specific accumulation in tumor, tumor-selective compounds, and compounds capable of incorporating into the structure of tumor cells. For the NCT of cancer patients, sodium mercaptododecaborate (BSH) and p-boronophenylalanine (BPA) were selected from several hundred of boron-containing compounds. In this paper, data on the distribution of BSH and BPA in the organism of animals with model tumors modeling those encountered in oncological patients are reviewed. Methods for increasing the boron uptake in tumor, based on the combined use of boron compounds and modification factors such as hyperthermia, effect of electric pulses on the tumor zone, administration of compounds possessing vasodilating properties and influencing the blood-brain barrier permeability, are considered.Despite progress in the surgery, beam therapy, and chemotherapy, problems encountered in the treatment of malignant neoplasms such as cerebral glioblastoma multiforme, gliomas, melanomas, and their metastatic manifestations are still far from being solved, since all methods are usually equally damaging both tumor and intact cells in the zone of action. One direction in solving the task of selectively treating malignant neoplasms is related to the development of neutron capture therapy (NCT) [1,2]. The NCT method is based on the interaction of two factors: low-energy ( £ 0.025 eV) "thermal" neutrons and a tumoraffin (oncotropic) preparation delivering to the tumor a chemical element with large cross section for thermal neutron capture. A number of such elements exist in the nature, but only two have found use in the NCT due to their physicochemical properties: boron-10 ( 10 B, 3838 barn) and gadolinium-157 ( 157 Gd, 255 000 barn). The interaction of thermal neutrons with Gd atoms leads to the generation of internal-conversion electrons, instantaneous gamma radiation, and Auger electrons with a total energy of 7.94 MeV per decay event [3,4], all these particles possessing a rather large range in tumor tissues. Despite much lower neutron capture cross section, 10 B atoms offer a significant advantage in comparison to 157 Gd, since the products of the former neutron capture reaction -a particles and 7 Li recoil nuclei (Fig. 1) -have a short range comparable with the cell size, which ensures a local evolution of the reaction energy. For this reason, the use of boron-containing compounds capable of selectively accumulating in a tumor provides cell death after the 10 B(n, a, g) 7 Li reaction predominantly in the tumor cells. This circumstance together with low general toxicity of boron mostly account for the fact that the effort in NCT development since the very beginning was mostly devoted to the search for boron-containing compounds capable of delivering born in necessary amount to the tumor cells.Any candidate boron-containing compound for boron neutron capture therapy (BNCT) has to obey two main requirements:(i) Ability to accumulate predo...

show abstract

Inhibition of growth of human breast cancer cells in culture by neutron capture using liposomes containing 10B

Cited by 16 publications

References 16 publications

Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment

Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment

Development history of boron delivery agents

Compounds for neutron capture therapy and their distribution in tumors and surrounding tissues of animals (A review)

Contact Info

Product

Resources

About